CN105963419A - Medicine composition with attenuated peach kernels - Google Patents
Medicine composition with attenuated peach kernels Download PDFInfo
- Publication number
- CN105963419A CN105963419A CN201610313037.9A CN201610313037A CN105963419A CN 105963419 A CN105963419 A CN 105963419A CN 201610313037 A CN201610313037 A CN 201610313037A CN 105963419 A CN105963419 A CN 105963419A
- Authority
- CN
- China
- Prior art keywords
- semen persicae
- cortex lycii
- extract
- attenuated
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title abstract description 9
- 230000002238 attenuated effect Effects 0.000 title abstract description 7
- 235000006040 Prunus persica var persica Nutrition 0.000 title abstract 6
- 240000006413 Prunus persica var. persica Species 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 29
- 210000000582 semen Anatomy 0.000 claims description 37
- 238000002481 ethanol extraction Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000469 ethanolic extract Substances 0.000 abstract description 4
- 231100000614 poison Toxicity 0.000 abstract description 2
- 230000007096 poisonous effect Effects 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 10
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 10
- 102000006995 beta-Glucosidase Human genes 0.000 description 9
- 108010047754 beta-Glucosidase Proteins 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 241000628997 Flos Species 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- 231100000691 up-and-down procedure Toxicity 0.000 description 3
- 235000003935 Hippophae Nutrition 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a medicine composition with attenuated peach kernels. The medicine composition with the attenuated peach kernels is prepared from a peach kernel ethanol extract and a cortex lycii radicis extract according to the mass ratio of 100:25 to 110. The composition provided by the invention adopts the cortex lycii radicis extract to attenuate and mix the peach kernel ethanol extract, so that not only is the attenuation effect ensured, but also the poisonous components are not added, and meanwhile, the original active ingredients of the peach kernels are also kept.
Description
Technical field
The invention belongs to field of food, relate to the health attenuated technology of medicine, the pharmaceutical composition being attenuated particularly to a kind of Semen Persicae.
Background technology
The recurrence being worth along with traditional food, the Chinese medicine with powerful exploitation potential has been widely applied to medicine and food neck
Territory, such as medicine-food two-purpose Semen Persicae.Research shows, the main antitussive of Semen Persicae, relievings asthma and analgesic component is the Semen Armeniacae Amarum of rich content
Glycosides.But, amygdaloside, in intestinal, easily by the beta-glucosidase enzyme hydrolysis of flora generation in intestinal, ultimately generates hydrogen cyanogen
Acid, hydrocyanic acid has stronger expiratory system toxicity, and this is also the reason place that Semen Persicae is poisonous.Therefore, need a kind of safety badly to have
The method of effect reduces Semen Persicae toxicity, and integration of edible and medicinal herbs and can be used for the Chinese medicine of health food, shown alleviate this problem can
Can property.
Summary of the invention
It is an object of the invention to provide the pharmaceutical composition of a kind of Semen Persicae attenuation.
Technical scheme is summarized as follows:
The pharmaceutical composition of a kind of Semen Persicae attenuation, is the ratio of 100:25～110 in mass ratio, by Semen Persicae ethanol extraction and ground
Cortex Lycii extract forms.
Preferably, the mass ratio of Semen Persicae ethanol extraction and Cortex Lycii extract is 100:61.
Advantages of the present invention:
It is demonstrated experimentally that the compositions of the present invention is to carry out being attenuated mixture to Semen Persicae ethanol extraction with Cortex Lycii extract, both ensured
Attenuating effects, maintains again the original active component of Semen Persicae.
Accompanying drawing explanation
Fig. 1 is the beta-glucosidase resolution ratio curve to variable concentrations amygdaloside.
Fig. 2 is the Cortex Lycii extract suppression ratio curve to beta-glucosidase of variable concentrations.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further illustrated.The following examples are to make those skilled in the art
Member better understood when the present invention, but does not impose any restrictions the present invention.
In various embodiments of the present invention, Semen Persicae ethanol extraction is made by following method: in proportion, takes the Semen Persicae after 100g pulverizes,
Add 4000mL ethanol, 250W ultrasound assisted extraction 45min, extract three times, united extraction liquid, be evaporated to extractum,
Dry, gained Semen Persicae ethanol extraction contains the amygdaloside of 24.63%.
In various embodiments of the present invention, Cortex Lycii extract is made by following method: in proportion, takes the Cortex Lycii after 100g pulverizes,
It is initially charged 4000mL ethanol, 250W ultrasound assisted extraction 45min, extracts twice, united extraction liquid, obtain ethanol extract；
In residue, add 4000mL water, 250W ultrasound assisted extraction 45min again, extract twice, united extraction liquid, obtain water and carry
Take liquid；Ethanol extract and aqueous extract mixing, be evaporated to extractum, dry.
Embodiment 1
The pharmaceutical composition of a kind of Semen Persicae attenuation, is the ratio of 100:61, by Semen Persicae ethanol extraction and Cortex Lycii in mass ratio
Extract forms.Under the conditions of this, Cortex Lycii extract is 90% to the suppression ratio of beta-glucosidase.
Embodiment 2
The pharmaceutical composition of a kind of Semen Persicae attenuation, is the ratio of 100:25, by Semen Persicae ethanol extraction and Cortex Lycii in mass ratio
Extract forms.Under the conditions of this, Cortex Lycii extract is 80% to the suppression ratio of beta-glucosidase.
Embodiment 3
The pharmaceutical composition of a kind of Semen Persicae attenuation, is the ratio of 100:110, by Semen Persicae ethanol extraction and Cortex Lycii in mass ratio
Extract forms.Under the conditions of this, Cortex Lycii extract is 93% to the suppression ratio of beta-glucosidase.
Embodiment 4
Screening has the Chinese medicine of beta-glucosidase enzyme inhibition activity
By following raw material: Radix Salviae Miltiorrhizae, Folium Perillae, Fructus Hippophae, Rhizoma Polygoni Cuspidati, Flos Caryophylli, Cortex Cinnamomi, Sanguis Draxonis, Ramulus Mori, Cortex Mori, Fructus Corni,
Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis, Galla Chinensis, Radix Sanguisorbae, Fructus Forsythiae, Fructus Canarii, Fructus Arctii, the Radix Angelicae Dahuricae, Rhizoma Coptidis, Radix Rehmanniae, Cortex Lycii,
Rhizoma Polygonati Odorati, Cortex Phellodendri, the Rhizoma Atractylodis Macrocephalae, Poria, Folium Artemisiae Argyi, Herba Euphorbiae Humifusae, Fructus Chebulae, Cortex Pseudolaricis, Flos Rosae Chinensis, Rhizoma Belamcandae, Herba Epimedii, Rhizoma Alpiniae Officinarum,
Rhizoma Smilacis Chinensis, Olibanum, the Cortex Eucommiae, Rhizoma Chuanxiong, Semen Arecae, Herb Gynostemmae Pentaphylli, the Rhizoma Anemarrhenae, Radix Glycyrrhizae, Radix Morindae Officinalis, Pericarpium Granati, Radix Et Rhizoma Rhei, Radix Puerariae, chicken
Caulis seu Radix Schisandrae Henryi, Ramulus Uncariae Cum Uncis, the Radix Astragali, Radix Angelicae Sinensis, Fructus Evodiae, Rhizoma Polygonati, Fructus Chaenomelis, Folium Isatidis, Semen Vaccariae, Semen Raphani, Herba Ephedrae, Fructus Crataegi,
Radix Rhodiolae, Cortex Magnoliae Officinalis, Folium Sennae, Fructus Momordicae, Radix Et Caulis Acanthopanacis Senticosi, Fructus Xanthii, Radix Bupleuri, Flos Lonicerae, Rhizoma Gastrodiae, respectively to its water extraction
Thing and ethanol extraction carry out initial in vitro Activity determination.
Rhizoma Belamcandae the most out, Radix Paeoniae Rubra, Folium Sennae, Caulis Spatholobi, Radix Angelicae Sinensis, Folium Artemisiae Argyi, Radix Sanguisorbae, Semen Arecae, the Radix Paeoniae Alba, Fructus Crataegi, the moon
Ji Hua, Herba Ephedrae, Pericarpium Granati, Poria, Radix Et Rhizoma Rhei, Cortex Mori, Fructus Hippophae, Herba Euphorbiae Humifusae, Flos Caryophylli, Cortex Cinnamomi, Cortex Pseudolaricis, Fructus Corni,
Rhizoma Alpiniae Officinarum, Fructus Chebulae, Fructus Chaenomelis, Fructus Canarii, Fructus Schisandrae Chinensis, the Radix Angelicae Dahuricae, Radix Glycyrrhizae, Cortex Lycii are for continuing screening material, to its water extract
IC is carried out with ethanol extraction50The mensuration of value.
Further to wherein activity preferably Fructus Chebulae, Fructus Chaenomelis, Fructus Canarii, Fructus Schisandrae Chinensis, the Radix Angelicae Dahuricae, Radix Glycyrrhizae, the ethanol extraction of Cortex Lycii
Thing and Flos Caryophylli, Fructus Chebulae, Fructus Chaenomelis, Fructus Canarii, the water extract of Cortex Lycii carry out suppressing the detection of type.It is shown in Table 1.
The extraction efficiency of table 1 extract, IC50Value and suppression type summary table
Considering activity and suppression type, choosing Cortex Lycii extract is that Semen Persicae is attenuated mixture medicine.
Embodiment 5
Substrate and the external optimization of inhibitor ratio
Method:
In 0.5mL reaction tube, it is sequentially added into the 0.5U/mL β-Portugal of 200 μ L kaliumphosphate buffer (pH=5.0), 50 μ L
Polyglycoside enzymatic solution and 50 μ L testing sample amygdaloside aqueous solutions (concentration be respectively as follows: 0.75mmol/L, 1.5mmol/L, 3
mmol/L、4.5mmol/L、6mmol/L、7.5mmol/L、9mmol/L、10.5mmol/L、12mmol/L、13.5mmol/L、
15mmol/L), at 37 DEG C of water-bath 30min, the 1mol/mL aqueous sodium carbonate adding 100 μ L is stop buffer, eventually
Only reaction, result is shown in Fig. 1.Amygdaloside concentration is when 7.12mmol/L, and the resolution ratio of amygdaloside is 90%.
In 0.5mL reaction tube, it is sequentially added into the 0.5U/mL β-Portugal of 150 μ L kaliumphosphate buffer (pH=5.0), 50 μ L
Mixed liquor that polyglycoside enzymatic solution and 50 μ L testing sample Cortex Lycii extracts add water (concentration be respectively as follows: 0.1mg/mL, 0.5
mg/mL、1mg/mL、2mg/mL、3mg/mL、4mg/mL、6mg/mL、8mg/mL、10mg/mL、13mg/mL、
16mg/mL), at 37 DEG C of water-bath 20min, the 7.12mmol/L amygdaloside aqueous solution of 50 μ L, 37 DEG C of water are added
Bath reaction 30min, the 1mol/mL aqueous sodium carbonate adding 100 μ L is stop buffer, terminates reaction, and result is shown in Fig. 2.Ground
When the concentration of the mixed liquor that Cortex Lycii extract adds water is 8.18mg/mL, it is 90% to the suppression ratio of beta-glucosidase.(i.e.,
7.12:8.18 (mmol/L:mg/mL) is the optimal proportion of amygdaloside and Cortex Lycii extract.The molecule matter of amygdaloside
Amount is 457.43g/mol, so 8.18mmol/L can be scaled 3.29mg/mL.Experiment gained Semen Persicae ethanol extraction after measured
The content of middle amygdaloside is 24.63%, therefore the optimal proportion of Semen Persicae ethanol extraction and Cortex Lycii extract is 13.36:8.18
(mg/mL:mg/mL) it is, 100:61 after embodiment 1 conversion.In like manner, the Cortex Lycii extract of embodiment 2 and 3 adds water
Mixed liquid concentration be respectively 3.4mg/mL and 14.8mg/mL, be respectively 100:25 and 100:110 after optimal proportion conversion.)
Can be drawn by Fig. 2, the concentration of the mixed liquor that Cortex Lycii extract adds water is when 3.4～14.8mg/mL, and its suppression exists
Near 90%.In the vitro reactions system containing beta-glucosidase 0.5U/mL, 100:25～110 Semen Persicae ethanol extractions and
The ratio effect of Cortex Lycii extract is preferable.
Embodiment 6
The internal checking of attenuating effects
Method:
Use " the Guideline for testing of chemicals:Acute oral that the Organization of Economy and Cooperation Development issues
Toxicity-up-and-down procedure " in " upper purgation " introduced, ask for " Semen Persicae ethanol extraction " and " present invention's
Compositions " half lethal dose (LD50): will be purchased from the 20～25g of Chinese Academy of Medical Sciences's Experimental Animal Center (Beijing)
Kunming mouse, under 22 ± 3 DEG C of constant temperature and 50 ± 10% damp conditions, 12h light dark cycle raise.During experiment, little
It is administered after Mus fasting 3～4h, 4h situation before Continuous Observation, and the situation within 3h routine observation 24h, the most often
It is observed, continuous 14 days.This method chooses the concentration of 5000mg/kg as limiting proof load.With 1290mg/kg for detection
Original measurement.Then based on observed result in 48h, according to method regulation in dosage range and dose point on (1290mg/kg,
1750mg/kg, 2300mg/kg, 3100mg/kg, 4100mg/kg, 5000mg/kg) add and subtract successively, until having tested.
Finally compare to obtain value, verification the verifying results.The results are shown in Table 2.Explanatorily after Cortex Lycii and Semen Persicae mixture, hence it is evident that reduce the toxicity of Semen Persicae.
The internal the result table of table 2 Semen Persicae attenuating effects
Note: toxicity grading is with reference to Environmental health research institute, NIH, U.S. Public Heath Service, health and mankind's service
" the The revised Up-and-Down procedure:A test method for determining the acute oral toxicity of of portion's writing
Chemicals " in " Up-and-Down Procedure (UDP) Peer Panel Report, July 25,2000Meeting "
Finally illustrating, preferred embodiment above is only in order to illustrate technical scheme and unrestricted, although by above-mentioned
The present invention is described in detail by preferred embodiment, it is to be understood by those skilled in the art that can in form and
In details, it is made various change, without departing from claims of the present invention limited range.
Claims (2)
1. a pharmaceutical composition for Semen Persicae attenuation, is characterized in that the ratio in mass ratio for 100:25～110, Semen Persicae ethanol carries
Take thing and Cortex Lycii extract composition.
Pharmaceutical composition the most according to claim 1, is characterized in that described Semen Persicae ethanol extraction and the quality of Cortex Lycii extract
Ratio is 100:61.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610313037.9A CN105963419A (en) | 2016-05-11 | 2016-05-11 | Medicine composition with attenuated peach kernels |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610313037.9A CN105963419A (en) | 2016-05-11 | 2016-05-11 | Medicine composition with attenuated peach kernels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963419A true CN105963419A (en) | 2016-09-28 |
Family
ID=56991684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610313037.9A Pending CN105963419A (en) | 2016-05-11 | 2016-05-11 | Medicine composition with attenuated peach kernels |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963419A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110531017A (en) * | 2019-09-12 | 2019-12-03 | 北方民族大学 | A kind of method of molecular networkization analysis root bark of Chinese wolf-berry compound structure |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101836945A (en) * | 2010-04-13 | 2010-09-22 | 武汉大学 | Chinese medicinal hair dye and preparation method thereof |
| CN102100765A (en) * | 2009-12-18 | 2011-06-22 | 天津宏仁堂药业有限公司 | Processing technique of peach kernels |
-
2016
- 2016-05-11 CN CN201610313037.9A patent/CN105963419A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100765A (en) * | 2009-12-18 | 2011-06-22 | 天津宏仁堂药业有限公司 | Processing technique of peach kernels |
| CN101836945A (en) * | 2010-04-13 | 2010-09-22 | 武汉大学 | Chinese medicinal hair dye and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴巧凤等: "桃核承气汤中桃仁单煎与桃仁甘草合煎的苦杏仁苷含量变化研究", 《浙江中医药大学学报》 * |
| 宁娜等: "地骨皮的化学成分与药理作用", 《现代药物与临床》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110531017A (en) * | 2019-09-12 | 2019-12-03 | 北方民族大学 | A kind of method of molecular networkization analysis root bark of Chinese wolf-berry compound structure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100532703B1 (en) | Composition comprising a crude drug complex for preventing and treating gastrointestinal dyskinetic disease | |
| CN103768537B (en) | Traditional Chinese medicine composition for treating qi-stagnation and blood stasis type angina pectoris | |
| CN102416139B (en) | Chinese medicine composition for treating breast diseases | |
| CN101513519B (en) | Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof | |
| CN104162057A (en) | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof | |
| Noh et al. | A systematic review of herbal medicine for chemotherapy induced peripheral neuropathy | |
| WO2010009030A2 (en) | Method and composition for enhancing fertility | |
| CN102940846B (en) | Traditional Chinese medicine composition for treating atrophic gastritis as welln as preparation method and application of composition | |
| CN103784888A (en) | Traditional Chinese medicine for treating coronary atherosclerotic heart disease caused by qi deficiency and blood stasis | |
| CN104784562B (en) | A kind of external used medicine for the treatment of breast carcinoma and preparation method thereof | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN105963419A (en) | Medicine composition with attenuated peach kernels | |
| CN102626478A (en) | Externally used Chinese herbal medicine compound for treating lumbar muscle strain for years | |
| CN100371012C (en) | Medicinal composition, and its preparing method and use | |
| CN104383024A (en) | Chronic dysentery preparation capable of invigorating spleen and supplementing qi and preparation method | |
| CN102228591B (en) | Preparation method of oral medicinal preparation for regulating menstruation and stopping pains | |
| CN110404030A (en) | A kind of Chinese medicine composition of chronic gastritis and preparation method thereof | |
| CN108635457A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating constipation | |
| CN101028319B (en) | Chinese-medicine compound preparation against coronary heart disease and its production | |
| CN104107242B (en) | A kind of Chinese medicine composition for the treatment of hyperthyroidism and its production and use | |
| CN116832132B (en) | Chinese medicinal composition and preparation for relieving pain and numbness, and preparation method and application thereof | |
| CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
| Yoon et al. | Analysis of sulfur dioxide residue in commercial medicinal herbs in Seoul (2009) | |
| Kim et al. | The Effect of Yijung-tang for Chronic Gastritis: A Systemic Review and Meta-Analysis | |
| CN104784351B (en) | External used medicine of a kind of Hepatoma therapy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |
|
| WD01 | Invention patent application deemed withdrawn after publication |